» Articles » PMID: 23200935

Disparate Adjuvant Properties Among Three Formulations of "alum"

Overview
Journal Vaccine
Date 2012 Dec 4
PMID 23200935
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Aluminum adjuvants, commonly referred to as "alum," are the most widespread immunostimulants in human vaccines. Although the mechanisms that promote humoral responses to alum-adsorbed antigens are still enigmatic, alum is thought to form antigen depots and induce inflammatory signals that, in turn, promote antibody production. It was recently noted that Imject(®) alum, a commercial aluminum-containing adjuvant commonly used in animal studies, is not the physicochemical equivalent of aluminum adjuvant present in human vaccines. This difference raises concerns about the use of Imject(®) alum in animal research as a model for approved aluminum adjuvants. Here, we compared the capacity of Imject(®) alum, Alhydrogel(®), and a traditional alum-antigen precipitate to induce humoral responses in mice to the hapten-carrier antigen, NP-CGG [(4-hydroxy-3-nitrophenyl)acetyl-chicken γ-globulin]. The magnitude of humoral responses elicited by Alhydrogel(®) and precipitated alum was significantly greater than that induced by Imject(®) alum. The strength of the humoral responses elicited by different alum formulations was correlated with the quantity of pro-inflammatory cytokines induced and the numbers of inflammatory cells at the site of immunization. Moreover, Imject(®) exhibited a severely reduced capacity to adsorb protein antigens compared to Alhydrogel(®) and precipitated alum. These findings reveal substantial differences in the immunostimulatory properties of distinct alum preparations, an important point of consideration for the evaluation of novel adjuvants, the assessment of new alum-based vaccines, and in mechanistic studies of adjuvanticity.

Citing Articles

Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.

Su Z, Boucetta H, Shao J, Huang J, Wang R, Shen A Acta Pharm Sin B. 2024; 14(11):4665-4682.

PMID: 39664431 PMC: 11628803. DOI: 10.1016/j.apsb.2024.09.012.


A reactogenic "placebo" and the ethics of informed consent in Gardasil HPV vaccine clinical trials: A case study from Denmark.

Tomljenovic L, McHenry L Int J Risk Saf Med. 2024; 35(2):159-180.

PMID: 38788092 PMC: 11191454. DOI: 10.3233/JRS-230032.


A Food Matrix Triggers a Similar Allergic Immune Response in BALB/c Mice Sensitized with Native, Denatured, and Digested Ovalbumin.

Aramburo-Galvez J, Tinoco-Narez-Gil R, Arvizu-Flores A, Figueroa-Salcido O, Mora-Melgem J, Islas-Rubio A Life (Basel). 2023; 13(8).

PMID: 37629590 PMC: 10455175. DOI: 10.3390/life13081733.


Aluminum Adjuvants-'Back to the Future'.

Laera D, HogenEsch H, OHagan D Pharmaceutics. 2023; 15(7).

PMID: 37514070 PMC: 10383759. DOI: 10.3390/pharmaceutics15071884.


Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.

de Oliveira N, Santos F, Dos Santos V, Maia M, Oliveira T, Dellagostin O Pathogens. 2023; 12(6).

PMID: 37375478 PMC: 10305058. DOI: 10.3390/pathogens12060787.


References
1.
Tesch H, Takemori T, Rajewsky K . The immune response against anti-idiotope antibodies II. The induction of antibodies bearing the target idiotope (Ab3 beta) depends on the frequency of the corresponding B cells. Eur J Immunol. 1983; 13(9):726-32. DOI: 10.1002/eji.1830130907. View

2.
Jacob J, Kelsoe G . In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med. 1992; 176(3):679-87. PMC: 2119370. DOI: 10.1084/jem.176.3.679. View

3.
Gottwein J, Blanchard T, Targoni O, Eisenberg J, Zagorski B, Redline R . Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis. 2001; 184(3):308-14. DOI: 10.1086/322032. View

4.
Rao K, He Y, Kalyanasundaram R . Expression of a 28-kilodalton glutathione S-transferase antigen of Schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential. Clin Diagn Lab Immunol. 2003; 10(4):536-41. PMC: 164271. DOI: 10.1128/cdli.10.4.536-541.2003. View

5.
Exley C, Siesjo P, Eriksson H . The immunobiology of aluminium adjuvants: how do they really work?. Trends Immunol. 2010; 31(3):103-9. DOI: 10.1016/j.it.2009.12.009. View